On 6 May 2024, Calliditas announced positive Phase 2 results for Setanaxib and Pembrolizumab for the treatment of head and neck cancer. The trial was randomized, placebo-controlled, and double-blinded and patients completed at least 15 weeks of treatment with 800mg setanaxib administered twice daily with 200mg pembrolizumab administered intravenously every three weeks. Reportedly, the study showed significant improvements in both progression-free survival (PFS) and overall survival (OS), along with notable changes in tumour biology.
Calliditas is conducting further Phase 2 setanaxib trials for treating primary biliary cholangitis, idiopathic pulmonary fibrosis, and Alport syndrome.